Urology

  • MINIRIN®
    MINIRIN®
    (desmopressin)
    (desmopressin)

    Urology
  • MINIRIN® (desmopressin)

    MINIRIN® (desmopressin) is indicated for the treatment of bedwetting in children and nocturia in adults. Both conditions are usually caused by an overproduction of urine at night, and MINIRIN acts on the kidneys to reduce this. Bedwetting can be traumatic for children, affecting their well-being and self-esteem. For adults with nocturia, waking up several times a night to urinate can lead to sleep deprivation affecting a patient's quality of life.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

  • NOCDURNA®
    NOCDURNA®
    (desmopressin)
    (desmopressin)

    Urology
  • NOCDURNA® (desmopressin)

    NOCDURNA® (desmopressin) is indicated for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. Nocturia, the need to awaken at night to pass urine, is a complex medical condition with various contributing factors. The night-time overproduction of urine, nocturnal polyuria, is responsible for nocturia in up to 88% of cases. NOCDURNA® once-daily lyophilisate tablets are administered sublingually (without the need for water) in gender specific low doses, tailored specifically for men (50 mcg) and women (25 mcg).

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

  • FIRMAGON®
    FIRMAGON®
    (degarelix)
    (degarelix)

    Urology
  • FIRMAGON® (degarelix)

    FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used. Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth.

     

    To date, FIRMAGON has been approved in 74 countries.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

  • TESTIM®
    TESTIM®
    (testosterone)
    (testosterone)

    Urology
  • TESTIM® (testosterone)

    TESTIM®* is a testosterone replacement treatment for men with low levels of testosterone.

    TESTIM is a clear gel that delivers testosterone into the body through the skin. Once TESTIM is absorbed, it enters the bloodstream and raises testosterone levels.

    (*TESTIM is a registered trademark of Auxilium Pharmaceuticals, Inc. - Ferring markets TESTIM in Europe under license from Auxilium Pharmaceuticals, Inc.)

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

Headquarters

Ferring International Center S.A.
Ch. de la Vergognausaz 50
1162 Saint-Prex
Switzerland

Tel:  +41 58 301 00 00
Fax: +41 58 301 00 10

Contact

GLOBAL LOCATOR